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Within the first week of the disease, acute kidney injury (AKI) is among the most common causes of mortality in acute pancreatitis
(AP). Recently, serum angiopoietin-2 (Ang-2) has been associated with hyperdynamic state of the systemic circulation. The aim
of this study was to examine the associations between Ang-2 and the clinical AP severity during the first 72 hours of the disease,
and organ disfunction, including AKI.Methods. Study included patients admitted to the surgery ward, diagnosed with AP. AKI was
diagnosed according to KDIGO guidelines and renal failure according tomodifiedMarshall scoring system. Ang-2 was determined
in serum with ELISA. Results. AP was classified as mild (MAP) in 71% of patients, moderately severe (MSAP) in 22%, and severe
(SAP) in 8%. During the first 72 hours of AP, 11 patients developed AKI and 6 developed renal failure. Ang-2 at 24, 48, and 72
hours following the onset of AP symptoms significantly predicted SAP and MSAP, as well as AKI and renal failure. Also, Ang-2
significantly correlated with acute phase proteins as well as with the indicators of renal disfunction. Conclusions. SerumAng-2 may
be a relevant predictor of AP severity, in particular of the development of AP-renal syndrome.
1. Introduction
Destabilization of the vascular endothelium as well as escape
of fluid from the vascular bed is one of the main factors
leading to vasodilatation, decrease in blood pressure, and
the development of early complications of acute pancreatitis
(AP), which clinically manifest themselves as shock and
developing organ failure [1, 2]. The patient’s transfer to the
intensive care unit, initiation of intensive fluid resuscitation
within the first 12–24 hours of the onset of severe acute
pancreatitis (SAP), close monitoring of organ function, and,
in case of acute kidney injury (AKI) in circulatory unstable
patients, implementation of continuous blood purification
techniques (continuous venovenous hemofiltration or con-
tinuous venovenous hemodiafiltration) may have a decisive
impact on the survival in this group of patients [1, 3, 4].
Such procedures are particularly justified because, in
nearly half of patients classified as SAP, organ failure is
diagnosed on admission, whereas the other 50% of patients
develop symptoms of organ failure in the first four days of
Hindawi Publishing Corporation
Mediators of Inflammation
Volume 2016, Article ID 5780903, 7 pages
http://dx.doi.org/10.1155/2016/5780903
2 Mediators of Inflammation
hospitalization [5, 6]. Moreover, more than a half of deaths
in SAP patients occur within the first week of the disease
[7]. AKI and acute respiratory distress syndrome are the
most common causes of mortality (70–80%) in this group of
patients [4, 8].
Currently, for the diagnostics of AKI, the risk, injury,
failure, loss, and end stage (RIFLE) and the Kidney Disease
ImprovingGlobalOutcomes (KDIGO) criteria are used. Both
criteria are based on the increase in serum creatinine and the
decrease in diuresis [4, 9]. In the treatment of AKI, it is critical
to quickly determine the cause of kidney injury (prerenal,
intrinsic, or postrenal). Unfortunately, an increase in serum
creatinine concentration usually occurs about 1-2 days after
kidney injury, which often delays the possibility of taking
action in the reversible phase of the disease.The limited value
of serum creatinine in the early phase of AKI as well as a bur-
densome necessity to monitor diuresis requiring (invasive)
urinary catheterization urges us to search for new biomarkers
of kidney injury. Early indicators include urine concentra-
tions of neutrophil gelatinase-associated lipocalin (uNGAL),
kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18)
[9].
One of the promising prognostic biomarkers of acute
pancreatitis is angiopoietin-2 (Ang-2) [10]. Studies by Whit-
comb et al. [11] showed that Ang-2 concentration is consid-
erably increased already at the time of the diagnosis of AP
and is significantly higher in patients with developing per-
sistent organ failure [11]. Watanabe et al. [12] demonstrated
a correlation between Ang-2 concentrations and perfusion
parameters using computed tomography [12]. IncreasedAng-
2 concentrations in blood are associated with hyperdynamic
state of the systemic circulation, and Ang-2 monitoring may
be helpful in the evaluation of the response to systemic treat-
ment, that is, fluid resuscitation, or antithrombotic therapy
[12].
Ang-2 belongs to a new class of angiogenic growth
factors that exerts a selective effect on the endothelium by
binding with Tie-2 receptor. It was demonstrated that Ang-
2 has an inhibitory effect on angiopoietin-1 binding to Tie-2,
which leads to destabilization of the vascular endothelium,
increased fluid leakage, and leukocyte adhesion [2, 12, 13].
Under physiologic conditions, Ang-2 is storedwithinWeibel-
Palade bodies, along with P-selectin, von Willebrand factor,
CD63, interleukin-8, and endothelin-1 [14]. Factors such as
hypoxia, inflammation, or mechanical injury may cause the
rapid release of Ang-2 into the systemic circulation [13, 14].
Ang-2 was proposed to be a link between angiogenic and
inflammatory pathway [14]. Serum concentrations of Ang-2
seem to reflect the extent of endothelial activation [2] and
may be useful in early clinical assessment of patients with
acute conditions, including AP.
The aim of this preliminary study was to assess Ang-
2 serum concentrations in patients with AP of various
severity in the early phase of the disease, that is, during
the first 72 hours of the disease, as well as to examine the
associations between Ang-2 and the clinical measures of the
severity of AP, in particular organ dysfunction, including
AKI.
2. Materials and Methods
The prospective observational study included 65 consecutive
adult patients (men and women) admitted with AP, hospi-
talized, and treated in the Department of Surgery, District
Hospital in Sucha Beskidzka, Poland, between January and
December 2014. AP was diagnosed according to the 2012
revision of the Atlanta classification, that is, when at least
two of the three following features were present: abdominal
pain consistent with AP (acute onset and persistent and
severe and epigastric pain); serum lipase or amylase activity
at least three times greater than the upper reference limit;
and the characteristic findings of AP on contrast-enhanced
computer tomography or magnetic resonance imaging or
transabdominal ultrasonography [15]. Only adult patients
who signed the informed consent for the studywere included.
Patients with symptoms of AP lasting longer than 24 hours
were excluded. Also, the exclusion criteria were chronic
pancreatitis, neoplasms, and chronic liver diseases such as
cirrhosis or viral hepatitis.
On the basis of the clinical evaluation of the severity ofAP,
the patients were assigned to one of the 3 groups: with mild
acute pancreatitis (MAP), moderately severe acute pancre-
atitis (MSAP), or severe acute pancreatitis (SAP). The MAP
group included patients who did not show any organ failure
or local complications. Patients with organ failure lasting less
than 48 hours (transient organ failure), local complications
(necrosis, acute necrotic collection, and walled-off pancreatic
necrosis), and/or exacerbation of comorbidity were assigned
to MSAP. Patients with persistent organ failure (lasting more
than 48 hours) and ≥1 local complications were assigned to
SAP [15].
AKI was diagnosed according to KDIGO guideline [16],
that is, when serum creatinine increased≥26.5 𝜇mol/Lwithin
48 hours or ≥1.5 times which is known or presumed to
occur within 7 days, or urine volume <0.5mL/kg/h for 6
hours.Organ failurewas diagnosed according to themodified
Marshall scoring system (MMSS), as cited in 2012 revision of
the Atlanta classification [15]; in particular, renal failure was
diagnosed in patients with serum creatinine ≥170 𝜇mol/L.
In order to determine serum Ang-2 concentrations
in healthy persons, a control group was recruited which
included 21 healthy volunteers (men and women) at the age
similar to that of the study group, without any pancreatic,
liver, or renal diseases.
The study protocol was approved by the Bioethics Com-
mittee of the Jagiellonian University (Approval number
KBET/247/B/2013).
2.1. Laboratory Tests. Blood and urine for laboratory tests
were collected at 24, 48, and 72 hours from the onset of
symptoms of AP. The routine laboratory tests and the mea-
surements of uNGAL, urine albumin, and urine creatinine
were performed at the day of collection, while serum samples
for serum NGAL (sNGAL) and Ang-2 measurements were
frozen in aliquots and stored in −70∘C. The routine tests
included complete blood count, urinalysis, serum amylase,
total calcium, albumin, urea, creatinine, glucose, C-reactive
protein, plasma fibrinogen, and D-dimer. All the routine
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Table 1: Clinical characteristics of patients included in the study.
Variable Patients with acutepancreatitis, 𝑛 = 65
Male sex, 𝑛 (%) 34 (52)
Age, years 62 ± 16
Etiology:
Gallstones, 𝑛 (%) 33 (51)
Alcohol, 𝑛 (%) 18 (28)
Hypertriglyceridemia, 𝑛 (%) 5 (8)
After ERCP, 𝑛 (%) 1 (2)
Others, 𝑛 (%) 8 (12)
Duration of pain until admission, hours 12 (6–24)∗
Duration of hospital stay, days 6 (5–12)∗
Severity:
Mild acute pancreatitis, 𝑛 (%) 46 (71)
Moderately severe acute pancreatitis, 𝑛 (%) 14 (22)
Severe acute pancreatitis, 𝑛 (%) 5 (8)
BISAP score:
=2 in the first 24 hours, 𝑛 (%) 12 (18)
≥3 in the first 24 hours, 𝑛 (%) 6 (9)
Comorbidities, 𝑛 (%) 50 (80)
SIRS, 𝑛 (%) 8 (12)
Pancreatic or peripancreatic necrosis, 𝑛 (%) 3 (5)
Peripancreatic fluid collections, 𝑛 (%) 5 (8)
Transient organ failure, 𝑛 (%) 6 (9)
Persistent organ failure, 𝑛 (%) 5 (8)
Pleural effusion, 𝑛 (%) 13 (20)
Acute kidney injury (KDIGO), 𝑛 (%) 11 (17)
Renal failure (MMSS), 𝑛 (%) 6 (9)
Antibiotic prophylaxis, 𝑛 (%) 31 (48)
Parenteral nutrition, 𝑛 (%) 3 (5)
Surgery, 𝑛 (%) 3 (5)
Early mortality/late mortality, 𝑛 (%) 0/3 (5)
∗Data are presented as median (lower–upper quartile).
𝑛 (%): number of patients in each category (percentage of the studied group
of 65 patients); BISAP: bedside index for severity in acute pancreatitis;
SIRS: systemic inflammatory response syndrome; ERCP: endoscopic retro-
grade cholangiopancreatography;MMSS:modifiedMarshall scoring system;
KDIGO: Kidney Disease Improving Global Outcomes.
laboratory tests and the measurements of uNGAL, urine
albumin, and urine creatinine were performed in the Depart-
ment of Laboratory Diagnostics, District Hospital in Sucha
Beskidzka, Poland. Complete blood counts were analyzed
in K
2
EDTA-anticoagulated blood with the Sysmex XE 2100
(SysmexCorp., Japan) automated hematology analyzer.Urine
NGAL concentrations were determined with the ARCHI-
TECTAnalyzer (Abbott Park, USA) using chemiluminescent
microparticle immunoassay. Ang-2 and sNGAL measure-
ments were performed in the Department of Diagnostics,
Chair of Biochemistry, Jagiellonian University Medical Col-
lege in Cracow, Poland. Serum NGAL concentrations were
measured with the Human Lipocalin-2/NGAL ELISA kits
(BioVendor, Brno, Czech Republic). Serum Ang-2 were
measured with the Quantikine ELISA Human Angiopoietin-
2 Immunoassay kits (R&D Systems, Minneapolis, USA).
2.2. Statistical Analysis. Data are shown as number of patients
(percentage of the group) for categories and median (25th–
75th percentile) or mean ± standard deviation for qualitative
variables, depending on distribution (as assessed using the
Shapiro-Wilk test). As the distributions of Ang-2 concentra-
tions significantly differed from normal, the nonparametric
tests were used. In detail, the differences between the groups
were studied using the Kruskal-Wallis ANOVA or Mann-
Whitney test, and the Spearman coefficient was used to assess
correlations. In order to study associations between Ang-2
and the measures of AP severity, simple and multiple logistic
regression were used, and the resulting odds ratios (ORs)
were reported with 95% confidence intervals (95% CIs).
Results were considered statistically significant at 𝑝 < 0.05.
TheStatistica 10.0 (StatSoft, Tulsa,USA) software packagewas
used for computations.
3. Results
In 71% of the study patients, AP was classified as mild, 22%
had MSAP, and 8% had SAP (Table 1). In most patients,
comorbidities were observed, most commonly hypertension
(22 patients, 34%), ischemic heart disease (18 patients, 28%),
and diabetes (10 patients, 15%); seven patients (11%) were
diagnosed with lung diseases and 3 (5%) with kidney diseases
(chronic kidney disease stages G3 in 2 patients and G4 in
4 patients). During the first 72 hours of AP, 11 patients
developed AKI according to the KDIGO criteria, including
stage 1 in 10 patients and stage 2 in one patient. According
to the modified Marshall scoring system, renal failure was
diagnosed in 6 patients. The detailed clinical characteristics
of the patients are presented in Table 1.
The median serum concentrations of Ang-2 were about
2 times higher in the whole group of AP patients than
in healthy controls (Table 2). However, the median Ang-
2 concentrations in MSAP and especially in SAP patients
were several times higher; the highest Ang-2 concentrations
in those groups were observed in serum samples taken 24
hours after the onset of symptoms of AP (Figure 1). The
median concentrations of urea, creatinine, and uNGAL in
the whole group of patients were within the reference ranges
(Table 2); however, 21 patients had an estimated glomerular
filtration rate (eGFR, based on MDRD equation) of less than
60mL/min/1.73m2 at 24 hours. The concentrations of urea
and creatinine were the highest at 24 hours and declined with
treatment (Table 2).
Ang-2 concentrations in the first 72 hours of AP signifi-
cantly predicted more severe disease (Table 3). In particular,
Ang-2 was a significant predictor of AKI (diagnosed based on
the KDIGO criteria) and renal failure (diagnosed according
to the modified Marshall scoring system) both in simple
analysis (Table 3) and after adjustment for age, sex, and
comorbidities, with ORs for AKI of 1.13 (1.01–1.26); 1.40 (1.11–
1.77); and 1.66 (1.18–12.32) and ORs for renal failure of 1.14
(1.02–1.28); 1.38 (1.10–1.74); and 1.84 (1.16–2.92) per 1 ng/mL
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Table 2: Laboratory data in the whole group of patients with acute pancreatitis (𝑛 = 65).
Variable 24 hours 48 hours 72 hours Reference values
Ang-2 [ng/mL] 3.18 (2.10–4.64) 3.33 (2.06–5.65) 3.12 (2.17–5.21) 1.73 ± 0.38 (range: 1.17–2.47)∗
CRP [mg/L] 14.00 (2.60–86.70) 119.70 (52.00–237.40) 104.80 (33.80–227.80) <5.0
WBC [×103/𝜇L] 11.21 (9.55–15.05) 9.80 (6.62–12.87) 8.43 (6.17–10.62) 4.00–10.00
HCT [%] 42.8 (39.1–45.5) 39.8 (35.1–42.8) 39.5 (35.4–42.2) F: 37.0–47.0/M: 40.0–54.0
PLT [×103/𝜇L] 234 (188–259) 197 (160–230) 206 (168–246) 150–350
Amylase [U/L] 1069 (618–1844) 162 (114–316) 92 (62–152) 62–220
Glucose [mmol/L] 7.81 (6.43–10.52) 5.39 (4.53–6.20) 5.28 (4.76–6.42) 3.3–5.6
Urea [mmol/L] 6.07 (4.31–7.97) 4.36 (3.35–7.33) 4.39 (3.35–5.44) 2.76–8.07
Creatinine [𝜇mol/L] 76.0 (65.7–99.1) 70.9 (62.4–90.7) 70.5 (57.7–89.1) 45.0–97.0
Fibrinogen [g/L] 2.80 (2.20–3.55) 3.87 (3.11–4.98) 4.49 (3.52–5.36) 1.8–3.5
D-dimer [𝜇g/L] 1683 (982–3293) 2076 (1300–4512) 2039 (975–4670) <500
sNGAL [𝜇g/L] 117.1 (70.8–208.5) 170.9 (100.8–237.1) 166.7 (102.2–216.6) F: 21.6–276.0/M: 14.4–169.2
uNGAL [𝜇g/L] 28.5 (15.5–57.0) 38.3 (16.5–95.3) 41.7 (17.0–65.1) <131.7
uACR [mg/g] 43.3 (21.0–79.4) 35.8 (20.8–89.5) 22.2 (14.2–92.3) <30
Data are presented as median (lower–upper quartile); ∗reference values established in 21 healthy controls; Ang-2: angiopoietin-2; CRP: C-reactive protein;



























































Figure 1: Serum angiopoietin-2 concentrations at 24, 48, and 72 hours after the onset of symptoms in patients with mild (MAP), moderately
severe (MSAP), and severe acute pancreatitis (SAP).Data are shown asmedian, 25th–75th percentile (boxes), and nonoutlier range (whiskers);
the points represent raw data.
increase in Ang-2 concentration at 24, 48, and 72 hours,
respectively. The concentrations of Ang-2 in patients with
a creatinine ≥170 𝜇mol/L (i.e., renal failure according to the
modified Marshal scoring system) are shown in Figure 2.
During the first 72 hours of AP, serum Ang-2 concen-
trations were significantly correlated with several laboratory
markers used in routine monitoring of AP patients, that
is, hematocrit, CRP, fibrinogen, or D-dimer (Table 4). Also,
Ang-2 negatively correlated with albumin and calcium con-
centrations at 48 and 72 hours (Table 4). Interestingly, Ang-
2 concentrations were positively correlated with markers
related to kidney function, that is, urea, sNGAL, and uNGAL,
during the first 48 hours, as well as creatinine and urine
albumin/creatinine ratio (uACR) during the entire study
(Table 4).
4. Discussion
Acute pancreatitis is a relatively common disease that in
most patients is mild or self-limiting; however, about 20%
of patients develop SAP associated with life-threatening
complications and a mortality of 20–30% [3, 9]. In older
patients (over 60 years of age), being obese (with a body
mass index greater than 30) or with chronic comorbidities
such as cardiovascular diseases or chronic kidney disease, the
mortality can reach 50–80% [4].
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Table 3: Angiopoietin-2 serum concentrations as a predictor of the severity of acute pancreatitis—results of simple logistic regression.
Dependent variable OR (95% CI), per 1 ng/mL increase in Ang-2 concentration
24 h 48 h 72 h
SAP 1.11 (1.01–1.22) 1.22 (1.03–1.46) 1.31 (1.07–1.60)
SAP or MSAP 1.29 (1.03–1.62) 1.58 (1.18–2.10) 1.70 (1.21–2.38)
BISAP in the first 24 hours ≥3 1.18 (1.04–1.33) 1.37 (1.12–1.68) 1.68 (1.21–2.20)
SIRS 1.25 (1.08–1.44) 1.49 (1.17–1.90) 1.48 (1.17–1.88)
AKI (KDIGO) 1.12 (1.02–1.24) 1.37 (1.12–1.68) 1.49 (1.17–1.90)
Renal failure (MMSS) 1.10 (1.01–1.21) 1.28 (1.08–1.52) 1.44 (1.15–1.80)
Pleural effusion NS 1.25 (1.06–1.47) 1.33 (1.10–1.63)
Death NS 1.27 (1.02–1.59) 1.42 (1.07–1.89)

























































p < 0.001p < 0.001 p < 0.001
Figure 2: Serum angiopoietin-2 concentrations at 24, 48, and 72 hours after the onset of symptoms in AP patients without renal failure (no
RF) andwith renal failure (RF) diagnosed according to themodifiedMarshall scoring system.Data are shown asmedian, 25th–75th percentile
(boxes), and nonoutlier range (whiskers); the points represent raw data.
In the present study, serum Ang-2 concentrations sig-
nificantly predicted the severity of AP in the early phase
of the disease. Also, the correlations were found between
Ang-2 and the laboratory markers of organ failure and
inflammation. In particular, Ang-2 significantly correlated
with the markers of kidney function and predicted both
AKI diagnosed according to KDIGO definition and renal
failure diagnosed according to modified Marshall scoring
system. The most reliable indicator of the severity of AP is
organ failure persisting more than 48 hours [17]. The 2012
revision of Atlanta classification recommends the assessment
of organ failure in AP with the use of the modified Marshall
scoring system [15]. Although the pathogenesis of AKI in
SAP is not fully elucidated, AKI significantly contributes to
mortality in AP. Especially susceptible are elderly patients
with reduced glomerular filtration and patients with history
of renal disease [16, 18]. In the revised Atlanta classification, a
patient’s age over 60 years and the presence of comorbidities
are recognized factors that significantly worsen the prognosis
and are associated with more severe AP; this should be taken
into account in the preliminary assessment of patients [15].
The results of the present study are in concordance with
the observations of Buddingh et al. [10] and Whitcomb et al.
[11] who reported the association between high serum Ang-
2 concentrations and SAP. Also, increased Ang-2 has been
recently associated with AKI [19].
Ang-2 is found in endothelial cells at the sites of vascular
remodeling, and its autocrine effect weakens the interac-
tion between endothelial cells and the surrounding cells,
especially pericytes [20]. Vascular endothelial growth factor
(VEGF) participates in the regulation of Ang-2 synthesis
[21]. In the initial phase of inflammation and in the absence
of VEGF, Ang-2 causes vascular regression by inducing
apoptosis of endothelial cells. In the systemic inflammatory
process, activated neutrophils and monocytes release a range
of enzymes such as phospholipase, elastase, or lipocalin-2,
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Table 4: Simple correlations between angiopoietin-2 and selected
variables during the first 72 hours of acute pancreatitis.
Variable 24 h 48 h 72 h
𝑅 𝑝 𝑅 𝑝 𝑅 𝑝
Age 0.27 0.033 0.26 0.035 0.26 0.036
Urea 0.36 0.003 0.41 <0.001 0.34 0.004
Creatinine 0.30 0.014 0.34 0.006 0.08 NS
CRP 0.48 <0.001 0.31 0.010 0.35 0.004
Albumin −0.23 NS −0.45 <0.001 −0.48 <0.001
Calcium −0.10 NS −0.44 <0.001 −0.43 <0.001
HCT −0.30 0.014 −0.36 0.003 −0.39 0.001
Fibrinogen 0.28 0.024 0.26 0.034 0.46 <0.001
D-dimer 0.40 0.001 0.44 <0.001 0.38 0.001
sNGAL 0.53 <0.001 0.52 <0.001 0.50 <0.001
uNGAL 0.59 <0.001 0.57 <0.001 0.52 <0.001
uACR 0.29 0.022 0.33 0.009 −0.01 NS
Ang-2: angiopoietin-2; HCT: hematocrit; NGAL: neutrophil gelatinase-
associated lipocalin in (s) serum and (u) urine; CRP: C-reactive protein;
uACR: urine albumin/creatinine ratio.
which intensifies degradation of phospholipids and may
lead to pancreatic and peripancreatic necrosis, as well as
intensified infiltration of other organs by inflammatory cells
[4]. In the present study, the concentrations of Ang-2 in the
systemic circulation were higher in patients than in controls
and correlated with inflammatory markers, that is, CRP,
fibrinogen, and NGAL concentrations in serum.
The renal endothelium is identified as a rich source of
Ang-2. Its release from the kidneys may increase due to
kidney injury, for example, in the course of AP [2, 14, 22,
23]. The correlations between Ang-2 and urea, creatinine,
uNGAL, and albuminuria support the association of Ang-2
with kidney injury. Urine NGAL is a promising biomarker of
AKI [24]. As a lowmolecular weight lipocalin, NGAL is easily
filtered by healthy glomeruli and then almost completely
absorbed in proximal tubules. The main fraction of uNGAL
in AKI is synthesized in the distal tubules of the glomeruli
in response to a damaging factor. In turn, increased sNGAL
concentrations are observed as a consequence of either
decreased glomerular filtration or increased synthesis by
activated neutrophils during inflammation. In AP, various
factors may lead to AKI, such as the effect of pancreatic
amylase on the renal microcirculation, hypoxemia, or a toxic
effect of excessively produced pancreatic phospholipase A
2
on the proximal tubules. However, the primary cause of the
development and progression of AKI in AP is associated
with hypovolemia associated with a decrease in filtration
pressure in the kidneys [4]. Hypovolemia is a result of a
systemic inflammatory state initiated by AP, associated with
vasodilation, escape of fluid into the third space, and increase
in intra-abdominal pressure. In patients with SAP, intra-
abdominal hypertension is observed, which significantly
contributes to the reduced perfusion of organs, including
the kidneys [25]. Dehydration and hypovolemia are also
intensified by vomiting or fever, often accompanying AP.
These factors cause a decrease in renal perfusion and, as
a consequence, damage to the renal tubules and the increase
in uNGAL concentrations.
In chronic kidney disease, albuminuria is a recognized
indicator of renal function, assessed along with eGFR; uACR
is recommended as a simple measure of albuminuria [18]. In
AKI, albuminuria may be associated with an injury to the
endothelium of glomerular vessels, being a part of a filtration
barrier. The other mechanism responsible for albuminuria
in AKI is an injury to the proximal tubule and reduced
albumin reabsorption from primary urine. Recently, albu-
minuria observed during the first 72 hours of ICU stay has
been associated with worse outcomes in patients with sepsis-
associated AKI [26]. On the other hand, the meta-analyses
performed by CKD prognosis consortium, published in 2015,
have recognized albuminuria (uACR) as a risk factor for
AKI [27, 28]. In the present study, uACR showed a positive
correlation with serum Ang-2 concentrations during the first
48 hours following the onset of AP. Tsai et al. [14] and Chang
et al. [29] reported the association between increased Ang-2
and albuminuria in patients with chronic kidney disease.
5. Conclusions
Early diagnosis and quick and accurate determination of
the cause are critical for the effective treatment of AKI. The
present study shows a correlation between increased serum
Ang-2 concentrations in patients with AP and deteriorated
renal function in the early phase of the disease. High Ang-2
concentrations correlated with uNGAL and uACR in patients
with AP in the “therapeutic window,” that is, within the
first 48 hours following the onset of AP. Thus, serum Ang-
2 may be a relevant predictor of the development of acute
pancreatic-renal syndrome and a useful tool for a clinician
in the evaluation of disease severity.
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